目的 探討核酪口服溶液聯(lián)合孟魯司特鈉片治療支氣管哮喘的臨床療效。方法 選取2013年4月—2017年11月深圳仁合醫(yī)院收治的76例支氣管哮喘患者作為研究對象，采用隨機數(shù)字表法將患者分為對照組和治療組，每組38例。對照組口服孟魯司特鈉片，1片/次，1次/d。治療組在對照組治療的基礎(chǔ)上口服核酪口服溶液，1支/次，3次/d。兩組患者均連續(xù)治療1個月。觀察兩組患者的臨床療效，同時比較兩組患者治療前后的血氣指標、肺功能指標和炎性因子水平。結(jié)果 治療后，對照組和治療組總有效率分別為80.7%、92.9%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組血氧分壓（pO₂）和pH值顯著升高，二氧化碳分壓（pCO₂）降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療后治療組血氣指標顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者最大呼氣流量（PEF）、一秒用力呼氣容積（FEV₁）、呼氣高峰流量（PEFR）和用力呼氣量占用力肺活量比值（FEV₁/FVC）均顯著增高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05），且治療后治療組肺功能指標顯著高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組白細胞介素-8（IL-8）、白細胞介素-17（IL-17）、基質(zhì)金屬蛋白酶抑制劑-1（TIMP-1）和基質(zhì)金屬蛋白酶-9（MMP-9）水平均顯著降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05），且治療后治療組炎性因子水平顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 核酪口服溶液聯(lián)合孟魯司特鈉片治療支氣管哮喘療效較好，可有效改善患者肺部功能，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effects of Nucleotide and Casein Oral Solution combined with Montelukast Sodium Tablets in treatment of bronchial asthma. Methods Patients (76 cases) with bronchial asthma in Shenzhen Renhe Hospital from April 2013 to November 2017 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Montelukast Sodium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Nucleotide and Casein Oral Solution, 1 tube/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the blood gas indexes, lung function indexes, and inflammatory factor levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.7% and 92.9%, respectively, and there were differences between two groups (P<0.05). After treatment, the pO₂ and pH value in two groups were significantly increased, but pCO₂ were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the blood gas indexes in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of PEF,FEV₁, PEFR, and FEV₁/FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the lung function indexes in the treatment group after treatment were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of IL-8, IL-17, TIMP-1, and MMP-9 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory factor levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Nucleotide and Casein Oral Solution combined with Montelukast Sodium Tablets has clinical curative effect in treatment of bronchial asthma, can effectively improve the pulmonary function of patients, which has a certain clinical application value.